Anticancer effect of deuterium depleted water - redox disbalance leads to oxidative stress

Xuepei Zhang, Massimiliano Gaetani, Alexey Chernobrovkin, Roman A. Zubarev*

Supplementary Figure captions:

Table S1. Common identified proteins in protein abundances analysis.

Table S2. Top 50 up and down regulated proteins specific for DDW and the abundance ratios to control.

Table S3. STRING analysis result of top 50 up regulated proteins

Table S4. STRING analysis result of top 50 down regulated proteins

Table S5. Result of time course analysis.

Table S6. Time course analysis of proteins most regulated by MTX.

Table S7. Time course analysis of proteins most regulated by DDW.

Table S8. Time course analysis of proteins most regulated by PCTL.

Table S9. Common proteins identified in redox proteomics result.

Table S10. Common peptides identified in redox proteomics result.

Table S11. Top 20 oxidized and reduced proteins.

Table S12. Oxidation levels of p62 peptides in DDW vs NW.

Table S13. Common proteins in cells growing in NW or DDW medium in redox result.

Table S14. Common peptides in cells growing in NW or DDW medium in redox result.

Table S15. Result of TPP analysis.

Table S16. R analysis of TPP result.

Table S17. STRING analysis result of overlap top 50 up regulated proteins with disbalance in oxidation -reduction level or changes in stability.

Table S18. STRING analysis result of top 50 down regulated proteins with disbalance in oxidation-reduction level or changes in stability.

Figure. S1. Survival of A549 cell line grown in media with different deuterium concentrations from 17-150 ppm.

Figure. S2. DDW effect on cell proliferation and dynamic analysis of regulation of DDW on proteome abundance.

Figure. S3. Inhibitory curve of auranofin.

Figure. S4. Validation of DDW anticancer mechanism.

| | Pathway ID | Pathway description | Observed gene count | False discovery rate |
|-----------------------|------------|---------------------|------------------------|----------------------|
| Cellular Component | GO:0005776 | autophagosome | 4 | 0.02 |
| (GO) | GO:0044754 | autolysosome | 2 | 0.0407 |
| UniProt Keywords | KW-0131 | Cell cycle | 9 | 0.0047 |
| | KW-0832 | Ubl conjugation | 16 | 0.0135 |

 Table S3. STRING analysis result of top 50 up regulated proteins

| | Pathway ID | Pathway description | Observed gene count | False discovery rate |
|-------------------------------|------------|--|---------------------|-------------------------|
| Biological | GO.0009165 | nucleotide biosynthetic process | 6 | 0.0325 |
| (GO) | GO.0010224 | response to UV-B | 3 | 0.0325 |
| Molecular Function | GO.0004748 | ribonucleoside-diphosphate reductase activity, thioredoxin disulfide as acceptor | 2 | 0.0183 |
| (GO) | GO.0016491 | oxidoreductase activity | 9 | 0.0183 |
| Cellular Component (GO) | GO.0005829 | cytosol | 20 | 0.0122 |
| | 4115 | p53 signaling pathway | 6 | 3.22E-06 |
| | 480 | Glutathione metabolism | 4 | 0.000816 |
| KEGG Pathways | 1100 | Metabolic pathways | 10 | 0.0242 |
| | 5161 | Hepatitis B | 4 | 0.0242 |
| | 5214 | Glioma | 3 | 0.0242 |

Table S4. STRING analysis result of top 50 down regulated proteins

| Oxidized | Como | Oxidation percentage (OX) | | | | | | | | | |
|----------|---------|---------------------------|--------|--------|--------|---------|--------|--------|--------|--------|-------|
| or | Gene | | A OV 2 | A OV 3 | C OV 1 | C O Y 2 | C OV 3 | | DOV 2 | DOV 2 | Donk |
| reduced | names | A-0A-1 | A-0A-2 | А-ОЛ-Э | 0.01 | C-0A-2 | C-0A-3 | D-0A-1 | D-0A-2 | D-0A-3 | Nalik |
| | HNRNPA1 | 0.4 | 0.6 | 2.8 | 3.0 | 3.6 | 2.5 | 11.2 | 11.5 | 11.0 | 1 |
| | RPAP3 | 2.2 | 3.2 | 5.3 | 12.1 | 4.9 | 12.1 | 42.3 | 33.6 | 42.9 | 2 |
| | p62 | 13.0 | 11.7 | 10.8 | 16.1 | 18.5 | 19.7 | 34.5 | 35.7 | 34.5 | 3 |
| | RPL32 | 1.5 | 7.7 | 6.4 | 8.2 | 4.4 | 3.5 | 30.8 | 20.7 | 28.5 | 4 |
| | CA12 | 57.7 | 60.2 | 57.3 | 65.4 | 61.8 | 61.6 | 76.3 | 75.2 | 77.0 | 5 |
| | DDX39B | 3.2 | 3.3 | 4.9 | 4.0 | 3.7 | 5.1 | 8.5 | 7.4 | 8.3 | 6 |
| | PACSIN2 | 16.8 | 12.8 | 14.1 | 16.5 | 14.4 | 9.9 | 25.8 | 27.2 | 24.9 | 7 |
| | ANXA2 | 2.7 | 1.5 | 2.4 | 5.1 | 5.9 | 5.7 | 12.1 | 12.2 | 13.6 | 8 |
| | FKBP4 | 6.0 | 6.2 | 6.8 | 7.0 | 8.0 | 7.4 | 16.5 | 23.7 | 16.3 | 9 |
| Ovidized | PSMD4 | 4.1 | 9.5 | 7.1 | 2.0 | 6.2 | 10.2 | 19.3 | 20.1 | 22.1 | 10 |
| Oxidized | RFC2 | 9.1 | 9.3 | 14.9 | 10.0 | 6.0 | 13.6 | 24.9 | 31.0 | 25.0 | 11 |
| | SARS2 | 1.2 | 2.3 | 4.2 | 1.2 | 1.8 | 1.9 | 13.3 | 17.5 | 9.5 | 12 |
| | MYO1B | 7.2 | 8.2 | 7.9 | 7.4 | 9.5 | 9.6 | 15.0 | 12.8 | 16.8 | 13 |
| | ACTR2 | 8.7 | 5.5 | 5.2 | 4.2 | 6.1 | 10.9 | 24.1 | 16.5 | 24.1 | 14 |
| | HSPA9 | 4.6 | 6.3 | 9.1 | 12.6 | 7.0 | 7.4 | 19.5 | 17.6 | 21.9 | 15 |
| | FSCN1 | 3.5 | 6.0 | 6.1 | 10.5 | 10.0 | 11.7 | 21.5 | 19.2 | 23.0 | 16 |
| | GSK3A | 4.9 | 2.3 | 8.1 | 10.7 | 8.0 | 9.5 | 25.8 | 17.9 | 26.2 | 17 |
| | CTPS1 | 7.1 | 7.9 | 8.4 | 7.8 | 7.1 | 7.7 | 15.4 | 12.0 | 11.4 | 18 |
| | TIPRL | 4.3 | 6.5 | 6.9 | 6.4 | 9.5 | 6.0 | 15.9 | 12.6 | 13.1 | 19 |
| | XPO5 | 7.6 | 9.6 | 10.8 | 1.7 | 3.8 | 5.8 | 30.1 | 18.3 | 27.8 | 20 |
| | ITGAV | 67.9 | 68.2 | 67.4 | 72.1 | 69.0 | 72.0 | 51.6 | 59.3 | 53.7 | 1 |
| | CELF1 | 23.2 | 14.8 | 25.5 | 25.9 | 22.9 | 26.8 | 5.6 | 8.8 | 6.8 | 2 |
| | GLG1 | 69.5 | 66.9 | 74.3 | 57.8 | 59.9 | 63.3 | 45.3 | 43.4 | 43.2 | 3 |
| | EIF4G2 | 15.0 | 14.3 | 16.6 | 7.9 | 18.2 | 17.5 | 4.5 | 2.7 | 3.6 | 4 |
| | JAG1 | 84.3 | 83.3 | 94.9 | 74.0 | 80.8 | 79.7 | 61.8 | 36.6 | 62.2 | 5 |
| | UBE2M | 11.4 | 17.6 | 16.8 | 10.9 | 11.1 | 15.3 | 3.9 | 2.4 | 8.1 | 6 |
| | TSPAN14 | 74.7 | 73.6 | 82.3 | 63.6 | 42.2 | 48.2 | 30.9 | 24.2 | 26.7 | 7 |
| | EWSR1 | 9.8 | 7.3 | 12.9 | 7.4 | 8.8 | 8.6 | 3.7 | 2.4 | 5.9 | 8 |
| | EPHA2 | 73.8 | 75.8 | 76.4 | 65.5 | 66.4 | 66.3 | 53.9 | 63.0 | 54.9 | 9 |
| | DIS3 | 16.8 | 26.7 | 22.3 | 18.6 | 19.2 | 21.3 | 13.2 | 7.3 | 14.2 | 10 |
| Reduced | ASNS | 23.0 | 22.5 | 26.6 | 11.4 | 16.8 | 12.1 | 4.9 | 2.5 | 7.3 | 11 |
| | HNRNPF | 6.8 | 10.0 | 16.8 | 16.0 | 16.9 | 17.3 | 2.3 | 5.4 | 4.8 | 12 |
| | SMC1A | 20.0 | 22.7 | 23.5 | 15.5 | 12.5 | 13.6 | 8.7 | 7.3 | 7.4 | 13 |
| | BSG | 51.0 | 51.0 | 46.0 | 78.1 | 80.7 | 87.0 | 23.5 | 18.4 | 35.5 | 14 |
| | ALCAM | 79.9 | 78.6 | 87.2 | 35.9 | 49.3 | 53.9 | 22.6 | 20.1 | 23.8 | 15 |
| | LMAN2 | 48.5 | 44.1 | 53.2 | 40.9 | 44.4 | 41.3 | 38.6 | 28.2 | 35.7 | 16 |
| | RPL36A | 7.3 | 7.1 | 8.2 | 4.8 | 6.9 | 8.2 | 4.7 | 3.0 | 5.2 | 17 |
| | DDB1 | 6.7 | 9.3 | 6.3 | 8.7 | 5.5 | 7.9 | 4.0 | 3.1 | 5.5 | 18 |
| | ERGIC3 | 76.2 | 78.2 | 81.0 | 48.6 | 53.2 | 49.4 | 35.8 | 33.1 | 37.1 | 19 |
| | RPS15A | 10.5 | 8.9 | 15.1 | 13.1 | 12.1 | 11.6 | 8.1 | 6.0 | 8.8 | 20 |

Table S11. Top 20 oxidized and reduced proteins. OX - oxdiation percentage, C - NW, A - auronafin, D - DDW.

| Sequence Mass | Masa | | Charges | C | Peptide | Peptide number Oxidation percentage (%) | | | | | | | | | |
|---------------|----------|------|---------|----------|---------|---|---------|-------|-------|-------|-------|----------|------|-------|-------|
| | Sequence | Mass | | Charges | Charges | Charges | Charges | Score | NW | DDW | NW-1 | NW-2 | NW-3 | DDW-1 | DDW-2 |
| 23-46 | 2453.99 | 5;6 | 114.63 | 1 | 1 | 13.53 | 9.45 | 11.73 | 18.83 | 17.62 | 18.51 | 0.005446 | | | |
| 119-139 | 2080.96 | 5 | 94.632 | 1 | 1 | 21.79 | 31.26 | 30.06 | 56.40 | 56.32 | 54.89 | 0.000732 | | | |
| 151-166 | 1719.66 | 5;6 | 96.208 | 1 | 1 | 15.99 | 21.19 | 22.08 | 42.50 | 41.99 | 45.63 | 0.000437 | | | |

Table S12. Oxidation levels of p62 peptides in DDW vs NW.

Table S17. STRING analysis result of overlap top 50 up regulated proteins withdisbalance in oxidation -reduction level or changes in stability

| | Pathway ID | Pathway description | Observed gene count | False discovery rate |
|------------------|------------|----------------------|---------------------|----------------------|
| KEGG Pathways | 5203 | Viral carcinogenesis | 4 | 0.00738 |

| | Pathway ID | Pathway description | Observed gene count | False discovery rate |
|-------------------------------|------------|--|------------------------|-------------------------|
| | GO.0016491 | oxidoreductase activity | 8 | 0.00167 |
| Molecular Function (GO) | GO.0004748 | ribonucleoside-diphosphate reductase activity, thioredoxin disulfide as acceptor | 2 | 0.00407 |
| | GO.0003824 | catalytic activity | 16 | 0.00774 |
| | 480 | Glutathione metabolism | 4 | 8.55E-05 |
| KEGG | 4115 | p53 signaling pathway | 4 | 0.000144 |
| Pathways | 1100 | Metabolic pathways | 8 | 0.00326 |
| | 240 | Pyrimidine metabolism | 3 | 0.0153 |

Table S18. STRING analysis result of top 50 down regulated proteins with disbalance in oxidation-reduction level or changes in stability



FIG. S1. Survival of A549 cell line grown in media with different deuterium concentrations from 17-150 ppm



FIG. S2. DDW effect on cell proliferation and dynamic analysis of regulation of DDW on proteome abundance. Abundance dynamic changes of DHFR (**A**), TUBB6 (**B** and p62 (**C**). **D** Statistical significance analysis of top 50 up and down regulated proteins in FITExP for each treatment at each time point. Error bars represent SEM, n = 2.



FIG. S3. Inhibitory curve of auranofin using Prism following logarithmic transformation of concentration and fitting curve using equation of log(inhibitor) vs. response – Variable slop (four parameters). Error bars represent SEM, n = 3.



FIG. S4. Validation of DDW anticancer mechanism. *A*, Combined effect of DDW and Auranofin on cell survival. *B*, Effect of DDW and Auranofin on cell survival in prensence of NAC. Error bars represent SEM with triplcates measurements, ns P>0.05, *P<0.05, **P<0.01, ***P<0.005 (two-tailed unparied t-tests).